Vor Biopharma Inc

More Details of Vor Biopharma Inc Company

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidates include tremtelectogene empogeditemcel (trem-cel), for the treatment of acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II multicenter, open-label, first-in-human study of trem-cel in patients with AML. Its other clinical trial and pipeline products are VCAR33 / VBP301, Trem-cel+VCAR33 Treatment, System CD33-CLL1 Treatment System, and VADC45.

Company Info

Company codeVOR

Company nameVor Biopharma Inc

IPO dateFeb 05, 2021

Founded at2015

CEODr. Robert Ang, M.D.

Number of employees159

Security typeOrdinary Share

Fiscal year-endFeb 05

Address100 Cambridgepark Drive

CityCAMBRIDGE

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02140

Phone16176556580

Websitehttps://www.vorbio.com/

Company codeVOR

IPO dateFeb 05, 2021

Founded at2015

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Tirtha Chakraborty, Ph.D.

Chief Scientific Officer and Head of Technical Operations

80.28K

-3.40%

Mr. Matthew R. Patterson

Non-Executive Independent Chairman of the Board

41.20K

+3.36%

Dr. Sven Ante (Bill) Lundberg, M.D.

Independent Director

29.43K

--

Mr. Erez Kalir

Independent Director

--

Mr. David Charles Lubner, CPA

Independent Director

--

Dr. Fouad Namouni, M.D.

Independent Director

--

Dr. Han Choi, M.D.

Chief Financial Officer

--

Dr. Robert Ang, M.D.

President, Chief Executive Officer, Director

--

Dr. Joshua B. (Josh) Resnick, M.D.

Independent Director

--

Ms. Daniella Beckman, CPA

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Tirtha Chakraborty, Ph.D.

Chief Scientific Officer and Head of Technical Operations

80.28K

-3.40%

Mr. Matthew R. Patterson

Non-Executive Independent Chairman of the Board

41.20K

+3.36%

Dr. Sven Ante (Bill) Lundberg, M.D.

Independent Director

29.43K

--

Mr. Erez Kalir

Independent Director

--

Mr. David Charles Lubner, CPA

Independent Director

--

Dr. Fouad Namouni, M.D.

Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholder

Update time: Fri, Apr 18

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

RA Capital Management, LP

31.75%

Reprogrammed Interchange LLC

31.22%

5AM Ventures

5.10%

Fidelity Management & Research Company LLC

5.07%

The Vanguard Group, Inc.

1.56%

Other

25.31%

Shareholder Statistics

Shareholder

Proportion

RA Capital Management, LP

31.75%

Reprogrammed Interchange LLC

31.22%

5AM Ventures

5.10%

Fidelity Management & Research Company LLC

5.07%

The Vanguard Group, Inc.

1.56%

Other

25.31%

Type

Shareholder

Proportion

Hedge Fund

33.29%

Corporation

31.22%

Investment Advisor

7.09%

Venture Capital

6.26%

Investment Advisor/Hedge Fund

2.57%

Individual Investor

0.70%

Research Firm

0.21%

Bank and Trust

0.01%

Other

18.65%

Institutional Shareholding

Update time: Tue, Mar 4

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

171

101.61M

81.40%

+39.01M

2024Q4

172

101.57M

81.78%

+39.14M

2024Q3

175

49.60M

72.03%

-12.93M

2024Q2

174

56.25M

82.04%

-8.25M

2024Q1

168

60.63M

88.57%

-4.75M

2023Q4

163

60.90M

89.54%

-3.77M

2023Q3

164

61.10M

90.20%

-4.10M

2023Q2

166

61.68M

92.10%

-1.24M

2023Q1

168

61.85M

93.27%

-1.28M

2022Q4

162

61.21M

94.78%

+26.97M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

RA Capital Management, LP

39.65M

31.75%

+16.90M

+74.28%

Dec 31, 2024

Reprogrammed Interchange LLC

38.97M

31.22%

+38.97M

--

Dec 30, 2024

5AM Ventures

6.36M

5.1%

--

Dec 31, 2024

Fidelity Management & Research Company LLC

6.33M

5.07%

-649.38K

-9.30%

Dec 31, 2024

The Vanguard Group, Inc.

1.94M

1.56%

-11.46K

-0.59%

Dec 31, 2024

Johnson & Johnson Innovation-JJDC, Inc.

1.07M

0.86%

--

Dec 31, 2024

Lynx1 Capital Advisors LLC

637.22K

0.51%

+637.22K

--

Dec 31, 2024

Sarissa Capital Management, L.P.

618.00K

0.49%

--

Dec 31, 2024

Ang (Robert M.D.)

646.69K

0.52%

+131.47K

+25.52%

Feb 06, 2025

Renaissance Technologies LLC

529.50K

0.42%

-226.51K

-29.96%

Dec 31, 2024

Related ETFs

Update time: Tue, May 6

Name

Proportion

Range Cancer Immunotherapy ETF

1.25%

iShares Micro-Cap ETF

0.01%

ProShares UltraPro Russell2000

0%

ProShares Hedge Replication ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Russell 2000 ETF

0%

Global X Russell 2000 ETF

0%

iShares Russell 2000 Value ETF

0%

Global X Russell 2000 Covered Call ETF

0%

Proshares Ultra Russell 2000

0%

Range Cancer Immunotherapy ETF

Proportion1.25%

iShares Micro-Cap ETF

Proportion0.01%

ProShares UltraPro Russell2000

Proportion0%

ProShares Hedge Replication ETF

Proportion0%

iShares Core S&P Total U.S. Stock Market ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Global X Russell 2000 ETF

Proportion0%

iShares Russell 2000 Value ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

Proshares Ultra Russell 2000

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

0.151USD

Vor Biopharma Inc

0.151

Overview

Company